-
Something wrong with this record ?
The influence of smoking, age and stage at diagnosis on the survival after larynx, hypopharynx and oral cavity cancers in Europe: The ARCAGE study
R. Abrahão, D. Anantharaman, V. Gaborieau, B. Abedi-Ardekani, P. Lagiou, A. Lagiou, W. Ahrens, I. Holcatova, J. Betka, F. Merletti, L. Richiardi, K. Kjaerheim, D. Serraino, J. Polesel, L. Simonato, L. Alemany, A. Agudo Trigueros, TV. Macfarlane,...
Language English Country United States
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
29405297
DOI
10.1002/ijc.31294
Knihovny.cz E-resources
- MeSH
- Survival Analysis MeSH
- Smoking adverse effects epidemiology MeSH
- Middle Aged MeSH
- Humans MeSH
- Laryngeal Neoplasms mortality pathology MeSH
- Hypopharyngeal Neoplasms mortality pathology MeSH
- Mouth Neoplasms mortality pathology MeSH
- Regression Analysis MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Neoplasm Staging MeSH
- Age Factors MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Geographicals
- Europe MeSH
Head and neck cancer (HNC) is a preventable malignancy that continues to cause substantial morbidity and mortality worldwide. Using data from the ARCAGE and Rome studies, we investigated the main predictors of survival after larynx, hypopharynx and oral cavity (OC) cancers. We used the Kaplan-Meier method to estimate overall survival, and Cox proportional models to examine the relationship between survival and sociodemographic and clinical characteristics. 604 larynx, 146 hypopharynx and 460 OC cancer cases were included in this study. Over a median follow-up time of 4.6 years, nearly 50% (n = 586) of patients died. Five-year survival was 65% for larynx, 55% for OC and 35% for hypopharynx cancers. In a multivariable analysis, we observed an increased mortality risk among older (≥71 years) versus younger (≤50 years) patients with larynx/hypopharynx combined (LH) and OC cancers [HR = 1.61, 95% CI 1.09-2.38 (LH) and HR = 2.12, 95% CI 1.35-3.33 (OC)], current versus never smokers [HR = 2.67, 95% CI 1.40-5.08 (LH) and HR = 2.16, 95% CI 1.32-3.54 (OC)] and advanced versus early stage disease at diagnosis [IV versus I, HR = 2.60, 95% CI 1.78-3.79 (LH) and HR = 3.17, 95% CI 2.05-4.89 (OC)]. Survival was not associated with sex, alcohol consumption, education, oral health, p16 expression, presence of HPV infection or body mass index 2 years before cancer diagnosis. Despite advances in diagnosis and therapeutic modalities, survival after HNC remains low in Europe. In addition to the recognized prognostic effect of stage at diagnosis, smoking history and older age at diagnosis are important prognostic indicators for HNC.
Cancer Registry of Norway Oslo Norway
Cancer Research Program Rajiv Gandhi Centre for Biotechnology Thiruvananthapuram Kerala India
Cancer Surveillance Section International Agency for Research on Cancer Lyon France
Center for Oral Health Research Newcastle University Newcastle upon Tyne United Kingdom
Department of Cardiac Thoracic and Vascular Sciences University of Padova Padova Italy
Department of Cardiovascular and Thoracic Sciences University of Padova Padova Italy
Department of Pathology Queen Elizabeth University Hospital Glasgow United Kingdom
Epidemiology Group University of Aberdeen Aberdeen United Kingdom
Genetic Cancer Susceptibility Group International Agency for Research on Cancer Lyon France
Genetic Epidemiology Group International Agency for Research on Cancer Lyon France
Infections and Cancer Biology Group International Agency for Research on Cancer Lyon France
Institut Català d'Oncologia IDIBELL L'Hospitalet de Llobregat Catalonia Spain
School of Medicine Dentistry and Nursing University of Glasgow Glasgow United Kingdom
Trinity College School of Dental Science Dublin Ireland
Unit of Cancer Epidemiology Aviano National Cancer Institute IRCCS Aviano Italy
Unit of Cancer Epidemiology Department of Medical Sciences University of Turin Turin Italy
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19012865
- 003
- CZ-PrNML
- 005
- 20190412094153.0
- 007
- ta
- 008
- 190405s2018 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1002/ijc.31294 $2 doi
- 035 __
- $a (PubMed)29405297
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Abrahão, Renata $u Genetic Epidemiology Group, International Agency for Research on Cancer, Lyon, France.
- 245 14
- $a The influence of smoking, age and stage at diagnosis on the survival after larynx, hypopharynx and oral cavity cancers in Europe: The ARCAGE study / $c R. Abrahão, D. Anantharaman, V. Gaborieau, B. Abedi-Ardekani, P. Lagiou, A. Lagiou, W. Ahrens, I. Holcatova, J. Betka, F. Merletti, L. Richiardi, K. Kjaerheim, D. Serraino, J. Polesel, L. Simonato, L. Alemany, A. Agudo Trigueros, TV. Macfarlane, GJ. Macfarlane, A. Znaor, M. Robinson, C. Canova, DI. Conway, S. Wright, CM. Healy, M. Toner, G. Cadoni, S. Boccia, T. Gheit, M. Tommasino, G. Scelo, P. Brennan,
- 520 9_
- $a Head and neck cancer (HNC) is a preventable malignancy that continues to cause substantial morbidity and mortality worldwide. Using data from the ARCAGE and Rome studies, we investigated the main predictors of survival after larynx, hypopharynx and oral cavity (OC) cancers. We used the Kaplan-Meier method to estimate overall survival, and Cox proportional models to examine the relationship between survival and sociodemographic and clinical characteristics. 604 larynx, 146 hypopharynx and 460 OC cancer cases were included in this study. Over a median follow-up time of 4.6 years, nearly 50% (n = 586) of patients died. Five-year survival was 65% for larynx, 55% for OC and 35% for hypopharynx cancers. In a multivariable analysis, we observed an increased mortality risk among older (≥71 years) versus younger (≤50 years) patients with larynx/hypopharynx combined (LH) and OC cancers [HR = 1.61, 95% CI 1.09-2.38 (LH) and HR = 2.12, 95% CI 1.35-3.33 (OC)], current versus never smokers [HR = 2.67, 95% CI 1.40-5.08 (LH) and HR = 2.16, 95% CI 1.32-3.54 (OC)] and advanced versus early stage disease at diagnosis [IV versus I, HR = 2.60, 95% CI 1.78-3.79 (LH) and HR = 3.17, 95% CI 2.05-4.89 (OC)]. Survival was not associated with sex, alcohol consumption, education, oral health, p16 expression, presence of HPV infection or body mass index 2 years before cancer diagnosis. Despite advances in diagnosis and therapeutic modalities, survival after HNC remains low in Europe. In addition to the recognized prognostic effect of stage at diagnosis, smoking history and older age at diagnosis are important prognostic indicators for HNC.
- 650 _2
- $a věkové faktory $7 D000367
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a senioři nad 80 let $7 D000369
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a nádory hypofaryngu $x mortalita $x patologie $7 D007012
- 650 _2
- $a nádory hrtanu $x mortalita $x patologie $7 D007822
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a nádory úst $x mortalita $x patologie $7 D009062
- 650 _2
- $a staging nádorů $7 D009367
- 650 _2
- $a regresní analýza $7 D012044
- 650 _2
- $a kouření $x škodlivé účinky $x epidemiologie $7 D012907
- 650 _2
- $a analýza přežití $7 D016019
- 651 _2
- $a Evropa $x epidemiologie $7 D005060
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Anantharaman, Devasena $u Cancer Research Program, Rajiv Gandhi Centre for Biotechnology, Thiruvananthapuram, Kerala, India.
- 700 1_
- $a Gaborieau, Valérie $u Genetic Epidemiology Group, International Agency for Research on Cancer, Lyon, France.
- 700 1_
- $a Abedi-Ardekani, Behnoush $u Genetic Cancer Susceptibility Group, International Agency for Research on Cancer, Lyon, France.
- 700 1_
- $a Lagiou, Pagona $u Department of Hygiene, Epidemiology and Medical Statistics, University of Athens Medical School, Athens, Greece.
- 700 1_
- $a Lagiou, Areti $u Department of Public Health and Community Health, School of Health Professions, Athens University of Applied Sciences, Athens, Greece.
- 700 1_
- $a Ahrens, Wolfgang $u Leibniz Institute for Prevention Research and Epidemiology - BIPS, Bremen, Germany. Institute of Statistics, Faculty of Mathematics and Computer Science, University Bremen, Bremen, Germany.
- 700 1_
- $a Holcatova, Ivana $u Institute of Hygiene and Epidemiology, 1st Faculty of Medicine, Charles University of Prague, Prage, Czech Republic.
- 700 1_
- $a Betka, Jaroslav $u Department of Otorhinolaryngology and Head and Neck Surgery, 1st Faculty of Medicine, Charles University of Prague, Prague, Czech Republic.
- 700 1_
- $a Merletti, Franco $u Unit of Cancer Epidemiology, Department of Medical Sciences, University of Turin, Turin, Italy.
- 700 1_
- $a Richiardi, Lorenzo $u Unit of Cancer Epidemiology, Department of Medical Sciences, University of Turin, Turin, Italy.
- 700 1_
- $a Kjaerheim, Kristina $u Cancer Registry of Norway, Oslo, Norway.
- 700 1_
- $a Serraino, Diego $u Unit of Cancer Epidemiology, Aviano National Cancer Institute, IRCCS, Aviano, Italy.
- 700 1_
- $a Polesel, Jerry $u Unit of Cancer Epidemiology, Aviano National Cancer Institute, IRCCS, Aviano, Italy.
- 700 1_
- $a Simonato, Lorenzo $u Department of Cardiovascular and Thoracic Sciences, University of Padova, Padova, Italy.
- 700 1_
- $a Alemany, Laia $u Institut Català d'Oncologia, IDIBELL, L'Hospitalet de Llobregat, Catalonia, Spain. CIBER en Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.
- 700 1_
- $a Agudo Trigueros, Antonio $u Institut Català d'Oncologia, IDIBELL, L'Hospitalet de Llobregat, Catalonia, Spain.
- 700 1_
- $a Macfarlane, Tatiana V $u Epidemiology Group, University of Aberdeen, Aberdeen, United Kingdom. Ninewells Hospital and Medical School, University of Dundee, Dundee, United Kingdom.
- 700 1_
- $a Macfarlane, Gary J $u Epidemiology Group, University of Aberdeen, Aberdeen, United Kingdom.
- 700 1_
- $a Znaor, Ariana $u Cancer Surveillance Section, International Agency for Research on Cancer, Lyon, France.
- 700 1_
- $a Robinson, Max $u Center for Oral Health Research, Newcastle University, Newcastle-upon-Tyne, United Kingdom.
- 700 1_
- $a Canova, Cristina $u Department of Cardiac, Thoracic and Vascular Sciences, University of Padova, Padova, Italy.
- 700 1_
- $a Conway, David I $u School of Medicine, Dentistry, and Nursing, University of Glasgow, Glasgow, United Kingdom.
- 700 1_
- $a Wright, Sylvia $u Department of Pathology, Queen Elizabeth University Hospital, Glasgow, United Kingdom.
- 700 1_
- $a Healy, Claire M $u Trinity College School of Dental Science, Dublin, Ireland.
- 700 1_
- $a Toner, Mary $u Trinity College School of Dental Science, Dublin, Ireland.
- 700 1_
- $a Cadoni, Gabriella $u Institute of Othorinolaringoiatry, Università Cattolica del Sacro Cuore, Fondazione Policlinico 'Agostino Gemelli', Rome, Italy.
- 700 1_
- $a Boccia, Stefania $u Section of Hygiene - Institute of Public Health, Università Cattolica del Sacro Cuore, Fondazione Policlinico 'Agostino Gemelli', Rome, Italy.
- 700 1_
- $a Gheit, Tarik $u Infections and Cancer Biology Group, International Agency for Research on Cancer, Lyon, France.
- 700 1_
- $a Tommasino, Massimo $u Infections and Cancer Biology Group, International Agency for Research on Cancer, Lyon, France.
- 700 1_
- $a Scelo, Ghislaine $u Genetic Epidemiology Group, International Agency for Research on Cancer, Lyon, France.
- 700 1_
- $a Brennan, Paul $u Genetic Epidemiology Group, International Agency for Research on Cancer, Lyon, France.
- 773 0_
- $w MED00002298 $t International journal of cancer $x 1097-0215 $g Roč. 143, č. 1 (2018), s. 32-44
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/29405297 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20190405 $b ABA008
- 991 __
- $a 20190412094212 $b ABA008
- 999 __
- $a ok $b bmc $g 1392175 $s 1051170
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 143 $c 1 $d 32-44 $e 20180223 $i 1097-0215 $m International journal of cancer $n Int J Cancer $x MED00002298
- LZP __
- $a Pubmed-20190405
